Key result
The NECTAR-HF trial is a phase II study designed to evaluate whether right vagal nerve stimulation attenuates cardiac remodeling in 96 patients with symptomatic heart failure.
Why the study?
Does vagal nerve stimulation improve left ventricular end systolic diameter in symptomatic heart failure patients with reduced ejection fraction?
RCT (n=96)
Single-blind
2:1
Yes
Does vagal nerve stimulation improve left ventricular end systolic diameter in symptomatic heart failure patients with reduced ejection fraction?
The NECTAR-HF trial is designed to evaluate whether right vagal nerve stimulation can attenuate cardiac remodeling and improve function in patients with symptomatic heart failure and reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
Failed to improve LVESD with right vagal stimulation in HFrEF; challenges prior signals and leaves open refined parameters for future trials.
Ferrari et al. (2014) conducted an RCT in Heart failure (n=96). Vagal nerve stimulation vs. Inactive VNS system was evaluated on Change in left ventricular end systolic diameter (LVESD) from baseline to 6 months. The NECTAR-HF trial is a phase II study designed to evaluate whether right vagal nerve stimulation attenuates cardiac remodeling in 96 patients with symptomatic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: